SageView Advisory Group LLC Takes Position in Organon & Co. (NYSE:OGN)

SageView Advisory Group LLC bought a new position in shares of Organon & Co. (NYSE:OGN) during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 9,782 shares of the company’s stock, valued at approximately $184,000.

A number of other large investors have also bought and sold shares of OGN. Norges Bank bought a new position in shares of Organon & Co. during the 4th quarter worth about $26,321,000. Sound Shore Management Inc. CT boosted its holdings in Organon & Co. by 35.2% in the fourth quarter. Sound Shore Management Inc. CT now owns 4,675,137 shares of the company’s stock worth $67,415,000 after acquiring an additional 1,216,522 shares in the last quarter. Allianz Asset Management GmbH grew its stake in Organon & Co. by 156.5% in the fourth quarter. Allianz Asset Management GmbH now owns 1,900,554 shares of the company’s stock valued at $27,406,000 after acquiring an additional 1,159,519 shares during the period. LSV Asset Management increased its holdings in shares of Organon & Co. by 34.0% during the first quarter. LSV Asset Management now owns 4,488,828 shares of the company’s stock valued at $84,390,000 after acquiring an additional 1,139,249 shares in the last quarter. Finally, Private Management Group Inc. raised its position in shares of Organon & Co. by 78.5% during the fourth quarter. Private Management Group Inc. now owns 2,335,238 shares of the company’s stock worth $33,674,000 after purchasing an additional 1,027,276 shares during the period. 77.43% of the stock is currently owned by institutional investors and hedge funds.

Organon & Co. Stock Up 0.4 %

NYSE:OGN traded up $0.08 on Friday, hitting $21.05. The stock had a trading volume of 267,939 shares, compared to its average volume of 2,295,550. The company has a debt-to-equity ratio of 181.35, a quick ratio of 1.15 and a current ratio of 1.65. The stock has a market cap of $5.41 billion, a P/E ratio of 5.13, a price-to-earnings-growth ratio of 0.98 and a beta of 0.85. The firm’s fifty day simple moving average is $20.82 and its two-hundred day simple moving average is $18.72. Organon & Co. has a 1 year low of $10.84 and a 1 year high of $24.08.

Organon & Co. (NYSE:OGN) last issued its earnings results on Thursday, May 2nd. The company reported $1.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.83 by $0.31. Organon & Co. had a negative return on equity of 360.57% and a net margin of 16.50%. The firm had revenue of $1.62 billion for the quarter, compared to analyst estimates of $1.57 billion. Analysts predict that Organon & Co. will post 4.29 earnings per share for the current year.

Organon & Co. Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, June 13th. Shareholders of record on Monday, May 13th were issued a dividend of $0.28 per share. This represents a $1.12 annualized dividend and a yield of 5.32%. The ex-dividend date of this dividend was Friday, May 10th. Organon & Co.’s dividend payout ratio (DPR) is presently 27.38%.

Analyst Ratings Changes

OGN has been the subject of several research reports. The Goldman Sachs Group lifted their price target on shares of Organon & Co. from $18.00 to $20.00 and gave the company a “neutral” rating in a research report on Friday, May 3rd. Piper Sandler boosted their target price on shares of Organon & Co. from $22.00 to $24.00 and gave the stock an “overweight” rating in a research report on Monday, April 29th.

About Organon & Co.

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.